XML 61 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8
BUSINESS SEGMENT INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2013
 
2012
 
2011
McKesson Corporation
 
19
%
 
23
%
 
26
%
Cardinal Health, Inc.
 
14
%
 
19
%
 
21
%
AmerisourceBergen Corporation
 
15
%
 
14
%
 
16
%
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
Selected geographic area information was as follows:
 
 
Total Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2013
 
2012
 
2011
 
2013
 
2012
United States
 
$
8,318

 
$
10,384

 
$
14,039

 
$
3,708

 
$
4,464

Europe
 
3,930

 
3,706

 
3,879

 
729

 
740

Rest of the World
 
3,295

 
3,204

 
3,237

 
142

 
129

Other(a) 
 
842

 
327

 
89

 
—

 
—

Total
 
$
16,385

 
$
17,621

 
$
21,244

 
$
4,579

 
$
5,333


(a)
Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
Revenue from External Customers by Products and Services [Table Text Block]
Total revenues of key products were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2013
 
2012
 
2011
Virology
 
 
 
 
 
 
Baraclude (entecavir)
 
$
1,527

 
$
1,388

 
$
1,196

Reyataz (atazanavir sulfate)
 
1,551

 
1,521

 
1,569

Sustiva (efavirenz) Franchise(a)
 
1,614

 
1,527

 
1,485

Oncology
 
 
 
 
 
 
Erbitux* (cetuximab)
 
696

 
702

 
691

Sprycel (dasatinib)
 
1,280

 
1,019

 
803

Yervoy (ipilimumab)
 
960

 
706

 
360

Neuroscience
 
 
 
 
 
 
Abilify* (aripiprazole)(b)
 
2,289

 
2,827

 
2,758

Metabolics
 
 
 
 
 
 
Bydureon* (exenatide extended-release for injectable suspension)
 
298

 
78

 
N/A

Byetta* (exenatide)
 
400

 
149

 
N/A

Forxiga (dapagliflozin)
 
23

 
—

 
N/A

Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)
 
877

 
709

 
473

Immunoscience
 
 
 
 
 
 
Nulojix (belatacept)
 
26

 
11

 
3

Orencia (abatacept)
 
1,444

 
1,176

 
917

Cardiovascular
 
 
 
 
 
 
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)
 
231

 
503

 
952

Eliquis (apixaban)
 
146

 
2

 
—

Plavix* (clopidogrel bisulfate)
 
258

 
2,547

 
7,087

 
 
 
 
 
 
 
Mature Products and All Other
 
2,765

 
2,756

 
2,950

Total Revenues
 
$
16,385

 
$
17,621

 
$
21,244


(a)
Includes $1,366 million in 2013, $1,267 million in 2012 and $1,203 million in 2011 presented in alliance and other revenue.
(b)
Includes $1,840 million in 2013, $2,340 million in 2012 and $2,303 million in 2011 presented in alliance and other revenue.